A2 BIO
LIVE

Serial Number

97796903

Owner

A2 Biotherapeutics, Inc.

Attorney

Joi A. White

Filing Date

Feb 15, 2023

Add to watchlist:

No watchlists yet
View on USPTO

A2 BIO Trademark

Serial Number: 97796903

A2 BIO is a trademark filed by A2 Biotherapeutics, Inc. on February 15, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

A2 Biotherapeutics, Inc. (10 trademarks)

Agoura Hills, CA 91301

Entity Type: 03

Trademark Details

Filing Date

February 15, 2023

Registration Date

Not Registered

Published for Opposition

December 26, 2023

Goods & Services

Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of inflammation and inflammatory diseases; biotherapeutics for the treatment and prevention of inflammation and inflammatory diseases; medicines for the treatment and prevention of inflammation and inflammatory diseases; pharmaceutical products for the treatment and prevention of inflammation and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of inflammation and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of inflammation and inflammatory diseases; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of inflammation and inflammatory diseases; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of inflammation and inflammatory diseases

Identification and development of therapeutic targets for others for the treatment and prevention of inflammation and inflammatory diseases; development of therapeutics and cell therapies for treatment and prevention of inflammation, and inflammatory diseases; research and development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of inflammation, and inflammatory diseases; providing scientific information relating to treatment and prevention of inflammation and inflammatory diseases

Manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of inflammation and inflammatory diseases using biological cells in the manufacturing process; custom manufacturing and engineering of biological cells, cellular targets, proteins, and antibodies for others for treatment and prevention of inflammation and inflammatory disease

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 13, 2026 EXRA
SOU EXTENSION 4 GRANTED
Feb 13, 2026 EX4G
SOU TEAS EXTENSION RECEIVED
Feb 10, 2026 EEXT
SOU EXTENSION 4 FILED
Feb 9, 2026 EXT4
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 26, 2025 EXRA
CORRECTED NOA E-MAILED
Aug 25, 2025 NOAC
SOU EXTENSION 3 GRANTED
Aug 25, 2025 EX3G
DIVISIONAL PROCESSING COMPLETE
Aug 25, 2025 DPCC
SOU TEAS EXTENSION RECEIVED
Aug 12, 2025 EEXT
SOU EXTENSION 3 FILED
Aug 11, 2025 EXT3
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 11, 2025 AITU
DIVISIONAL REQUEST RECEIVED
May 8, 2025 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
May 8, 2025 ERTD
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 20, 2025 EXRA
SOU EXTENSION 2 GRANTED
Feb 20, 2025 EX2G
SOU EXTENSION 2 FILED
Feb 19, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 19, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 19, 2024 EXRA
SOU EXTENSION 1 GRANTED
Aug 19, 2024 EX1G
SOU EXTENSION 1 FILED
Aug 19, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 19, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 20, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 26, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 26, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 6, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 17, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 17, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 17, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 17, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 17, 2023 CNEA
ASSIGNED TO EXAMINER
Nov 14, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 6, 2023 NWOS
NEW APPLICATION ENTERED
Feb 18, 2023 NWAP